| h-782e55f6 | DNMT1-Targeting Antisense Oligonucleotide Reset | 0.65 | 0.30 | DNMT1 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-bc5f270e |
| h-d40d2659 | HCN1-Mediated Resonance Frequency Stabilization Therapy | 0.65 | 0.40 | HCN1 | debated | 2026-04-02 | sda-2026-04-01-gap-004 |
| h-13bbfdc5 | Mitochondrial SPM Synthesis Platform Engineering | 0.65 | 0.20 | ALOX5 | debated | 2026-04-02 | sda-2026-04-01-gap-014 |
| h-e5f1182b | Epigenetic Reprogramming of Microglial Memory | 0.65 | 0.60 | DNMT3A, HDAC1/2 | debated | 2026-04-04 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| h-e37e76c0 | S100B as Active Pathogenic BBB-Disrupting Signal via RAGE/NF-κB/Claudin-5 Axis | 0.65 | 0.18 | S100B | proposed | 2026-04-26 | SDA-2026-04-26-gap-bbb-permeability-biomarker-20260426 |
| h-a1d97415 | Inflammatory State-Dependent Ketone Timing | 0.65 | 0.40 | IRAKM | proposed | 2026-04-17 | SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 |
| h-57862f8a | Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement | 0.65 | 0.20 | IDH2 | debated | 2026-04-02 | sda-2026-04-01-gap-004 |
| h-3e6ca50b2f | Activity-Dependent Synaptic Tagging via CREB-BDNF-TrkB Signaling | 0.65 | 0.52 | CREB1, BDNF, NTRK2 (TrkB) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062128-c84a87d9 |
| h-e3506e5a | Synthetic Biology Rewiring via Orthogonal Receptors | 0.65 | 0.50 | CNO | debated | 2026-04-02 | sda-2026-04-01-gap-009 |
| h-SDA-2026-04-26-gap | Endothelial miR-181c-5p Upregulation Drives Claudin-5 Repression and Paracellula | 0.65 | 0.43 | CLDN5 (Claudin-5) - regulated by miR-181c-5p | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260426-011448-7c85f5dc |
| h-SDA-2026-04-26-gap | Dominant-Negative Spliceosome Titration | 0.65 | 0.43 | U2AF2, SF3B1, PRPF8; splicing snRNPs | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260412-094853-199f4f1b |
| h-a3580b22 | Retromer-dependent retrograde endosomal signaling compartmentalization as biomar | 0.65 | 0.62 | VPS35, VPS26, VPS29 (retromer complex); TrkB/NTRK2 (cargo re | proposed | 2026-04-26 | SDA-2026-04-10-gap-debate-20260410-075000-7396040a |
| h-e6437136 | Ephrin-B2/EphB4 Axis Manipulation | 0.64 | 0.20 | EPHB4 | debated | 2026-04-02 | sda-2026-04-01-gap-005 |
| h-e003a35e | Oligodendrocyte Remyelination Enhancement | 0.64 | 0.60 | TREM2 | proposed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-e714137dd7 | MCU Calcium Overload via MFN2/GRP75/VDAC1 MAM Dysfunction | 0.64 | 0.62 | MFN2, GRP75 (HSPA9), MCU (MICU1/2) | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062141-739c7f1c |
| h-699c0d72 | Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy | 0.64 | 0.75 | | promoted | 2026-04-15 | SDA-2026-04-15-gap-pubmed-20260411-075356-20920528 |
| h-cb1d193197 | Microglial Metabolic Trained Immunity via mTOR-HIF1α Axis | 0.64 | 0.70 | MTOR/HIF1α | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062045-56983337 |
| h-8efcb4cf | H1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from Synapse Pruning to A | 0.64 | 0.52 | TREM2 | proposed | 2026-04-14 | SDA-2026-04-26-trem2-showcase |
| h-245c3e93 | White Matter Immune Checkpoint Restoration | 0.64 | 0.30 | CXCL10 | proposed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-8dc75e4072 | HDAC2 Phospho-Lock Window for Synaptic Gene Silencing | 0.64 | 0.72 | HDAC2 (phospho-S421) | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062039-7ef9980b |
| h-67d4435cb5 | Epigenetic Silencing of AIF1 Gene Locus by Chronic Inflammation | 0.64 | 0.55 | DNMT1/DNMT3A | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041439-306c2cdb |
| h-b34120a1 | Cell-Type Specific Metabolic Reprogramming | 0.64 | 0.30 | PPARA | proposed | 2026-04-14 | SDA-2026-04-03-gap-seaad-v4-20260402065846 |
| h-ed23619c | HDAC6 Selective Inhibition to Restore Acetylation Balance and Microtubule Stabil | 0.64 | 0.68 | HDAC6 | promoted | 2026-04-13 | SDA-2026-04-13-gap-debate-20260412-094556-86f36bb3 |
| h-var-ac50d1e3d1 | SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis | 0.64 | 0.65 | HK2/PFKFB3 | proposed | 2026-04-07 | sda-2026-04-01-gap-013 |
| h-7a5be68a9e | J-protein co-chaperone repertoire enables selective recognition of pathogenic co | 0.64 | 0.58 | DNAJB6, DNAJB2, HSPA8, HSPA1A | proposed | 2026-04-21 | SDA-2026-04-10-gap-debate-20260410-075012-32bac138 |
| h-var-7e118a66d8 | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | 0.64 | 0.72 | TREM2 | archived | 2026-04-07 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-var-a8c6c6ea92 | TREM2-Mediated Mitochondrial Dysfunction in Neurodegeneration | 0.64 | 0.80 | TREM2 | promoted | 2026-04-20 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-var-56a6156e67 | TREM2-Driven Senescence Biomarker Index for Predicting Neurodegeneration Risk | 0.64 | 0.78 | TREM2 | promoted | 2026-04-20 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-f7da6372 | Mitochondrial ATP/ADP Carrier Activity as Bioenergetic Recovery Metric | 0.64 | 0.40 | SLC25A4 | proposed | 2026-04-17 | SDA-2026-04-04-gap-debate-20260403-222618-c698b06a |
| h-8b7727c1 | Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding | 0.64 | 0.40 | CSGA | proposed | 2026-04-03 | SDA-2026-04-01-gap-20260401-225149 |
| h-var-1dc420e7d8 | CYP46A1 Suppression for Tau-Mediated Neurodegeneration | 0.64 | 0.35 | CYP46A1 | proposed | 2026-04-07 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| h-7e846ceb | Glycine-Rich Domain Competitive Inhibition | 0.64 | 0.55 | TARDBP | debated | 2026-04-02 | sda-2026-04-01-gap-006 |
| h-16ae38923d | Endosomal-Retromer Trafficking Defect as a Shared Sorting Failure | 0.64 | 0.68 | VPS35, VPS26, SORL1, SNX27 | proposed | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-metrep-b3a540aad7e | Caloric Restriction Mimetic Combination Therapy (Metformin + Resveratrol + Rapam | 0.64 | 0.75 | AMPK,PRKAA1,PRKAA2,SIRT1,MTOR,RPTOR,PPARGC1A,FOXO3,FOLH1 | proposed | 2026-04-28 | |
| h-metrep-a7cf1c8bed7 | mTORC1 Displacement from Lysosomal Membrane Enables TFEB Nuclear Translocation a | 0.64 | 0.75 | MTOR,RPTOR,TFEB,RragA,RragC,GABARAPL1,LAMP1,CTSD,ULK1 | proposed | 2026-04-28 | |
| h-377232dcc8 | LRRK2 G2019S Uncouples RAB29-Dependent Spatial Control from Kinase Activity (H7) | 0.64 | 0.62 | LRRK2,RAB29 | proposed | 2026-04-26 | SDA-2026-04-23-gap-debate-20260417-033119-54941818 |
| h-SDA-2026-04-26-gap | Circulating Endothelial Microvesicles Expressing Degraded Claudin-5 as Specific | 0.64 | 0.52 | CLDN5 fragments on CD31+/CD144+ EMVs | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260426-011448-7c85f5dc |
| h-SDA-2026-04-26-gap | Matrix Metalloproteinase-9 and TIMP-1 Ratio in Peripheral Blood as an Early Indi | 0.64 | 0.52 | MMP-9 (Matrix Metallopeptidase 9) / TIMP-1 ratio | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260426-011448-7c85f5dc |
| h-dcd960ac02 | HBOT at 1.5 ATA for 60 min induces hormetic response via Nrf2 activation, enhanc | 0.64 | 0.65 | NFE2L2 (Nrf2) | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| h-d7e5613a0f | Mitochondrial ROS from complex I and cardiolipin instability forms a local organ | 0.64 | 0.67 | NDUFV1; NDUFV2; MT-ND genes; cardiolipin-associated ETC comp | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-181140-0af1a353-debate |
| h-2e508abc40 | Iron Chelation Therapy Targeting the Labile Iron Pool | 0.64 | 0.68 | Labile iron pool (LIP) / Fenton chemistry | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-174000-6451afef-debate |
| h-1fd37610f6 | Anti-inflammatory microglial reprogramming via cystatin-C/TREM2 axis | 0.64 | 0.72 | TREM2/TYROBP | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-150544-e3a2eab9-debate |
| h-e67bc7eaca | Amyloid-beta induces secondary pericyte senescence after contractile and oxidati | 0.64 | 0.58 | APP/Aβ, EDN1, EDNRA, ROS | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-de5dfc4391 |
| h-caf71f08b9 | Colonic Th17/IL-17A Axis → Peripheral Immune Recruitment to SN and Neuronal Apop | 0.64 | 0.62 | RORC (RORγt), IL17A, IL17RA, IL17RC, CXCL9, CXCL10, CXCR3, C | proposed | 2026-04-22 | sda-2026-04-01-gap-20260401-225155 |
| h-3b76e515e0 | H7: mTOR Hyperactivity Blocks Autophagy, Permitting Tau Seeding | 0.64 | 0.70 | MTOR, ULK1, TFG | proposed | 2026-04-22 | SDA-2026-04-02-gap-ec-layer2-vulnerability |
| h-dbfa26403a | CDK5 Inhibition at Presynaptic Terminals Prevents Activity-Dependent Tau Release | 0.64 | 0.72 | CDK5 | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-052358 |
| h-8069fba1d5 | Neuronal TET1 Upregulation Reactivates Immediate-Early Genes and Restores Dendri | 0.64 | 0.72 | TET1/5hmC | proposed | 2026-04-22 | SDA-2026-04-04-gap-20260404-060512 |
| h-2901c57778 | Critical Period Hypothesis: The Therapeutic Window Closes When Neuronal Homeosta | 0.64 | 0.65 | NfL, p-tau217, p-tau231, ATF4, TOMM40 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-7bcf4b6c |
| h-0c9e2166ed | Small Molecule Modulation of Phase Separation | 0.64 | 0.60 | FUS, TDP-43, G3BP1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041428-53b81741 |
| h_seaad_002 | Heterogeneous astrocyte activation states differentially impact neuronal surviva | 0.64 | 0.78 | GFAP | promoted | 2026-04-04 | SDA-2026-04-04-analysis_sea_ad_001 |